-
1.发明授权MEDICINAL COMPOSITIONS FOR TREATING AND PREVENTING DISEASES BASED ON ABNORMAL BLOOD COAGULATION 有权医药组合物用于治疗和异常的预防混凝为本病
公开(公告)号：EP1240901B1
公开(公告)日：2008-09-10
申请号：EP00987688.9
申请日：2000-12-21
发明人： NAKATOMI, Yasushi , TOMOKIYO, Kazuhiko , ARAKI, Tatsuya , TESHIMA, Kaori , WATANABE, Tomoko , NAKAGAKI, Tomohiro
CPC分类号： A61K38/4846
摘要： Medicinal compositions for preventing and treating hemorrhagic symptoms associating abnormal blood coagulation which contain as the main active ingredient a combination of activated blood coagulation factor VII (FVIIa) with blood coagulation factor X (FX). These compositions contain no component mainly causing side effects, are highly safe and efficacious, and make it possible to easily control hemostatis. Thus, these compositions are usable in controlling the hemostatis of, for example, patients suffering from blood coagulation failure due to, for example, abnormality (including defect) in blood coagulation factors, in particular, carrying a blood coagulation factor inhibitor (antibody).
-
2.发明公开MEDICINAL COMPOSITIONS FOR PREVENTING AND TREATING HEMORRHAGIC DISEASES ASSOCIATING THROMBOPATHY 有权因子VIII或将触发因素thrombopathies出血性疾病关联的治疗
公开(公告)号：EP1240900A1
公开(公告)日：2002-09-18
申请号：EP00985824.2
申请日：2000-12-21
发明人： ARAKI, Tatsuya , TOMOKIYO, Kazuhiko , NAKATOMI, Yasushi , TESHIMA, Kaori , WATANABE, Tomoko , NAKAGAKI, Tomohiro
CPC分类号： A61K38/37 , Y10S514/802 , Y10S514/834
摘要： The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet count or platelet dysfunction, said composition comprising a hemostatic effective amount of Factor VIII and/or von Willebrand Factor. Also provided is a method for treating said bleeding, comprising administering a hemostatic effective amount of Factor VIII and/or von Willebrand Factor to patients suffering from bleeding disorders caused by platelet disorders.
摘要翻译： 本发明提供一种不会因血液凝固因子或血管性血友病因子缺陷引起的，而是由减少循环血小板计数或血小板功能障碍引起的用于治疗和预防由血小板疾病，引起出血性疾病的药物组合物，所述组合物包含止血有效量的 的因子VIII和/或血管性血友病因子。 这样提供了一种用于治疗所述出血，包括施用止血有效量的因子VIII和/或血管性血友病因子的从出血由血小板失调引起的疾病的患者的方法。
-
3.发明公开MEDICINAL COMPOSITIONS FOR TREATING AND PREVENTING DISEASES BASED ON ABNORMAL BLOOD COAGULATION 有权医药组合物用于治疗和异常的预防混凝为本病
公开(公告)号：EP1240901A1
公开(公告)日：2002-09-18
申请号：EP00987688.9
申请日：2000-12-21
发明人： NAKATOMI, Yasushi , TOMOKIYO, Kazuhiko , ARAKI, Tatsuya , TESHIMA, Kaori , WATANABE, Tomoko , NAKAGAKI, Tomohiro
CPC分类号： A61K38/4846
摘要： The present invention provides a pharmaceutical composition for treatment and prevention of hemorrhage associated with blood coagulation disorders, comprising activated Factor VII (FVIIa) and Factor X (FX) as an active ingredient. The pharmaceutical composition of the present invention contains no components causative side effects, is safe, highly efficacious, and easy to manage hemostasis. The pharmaceutical composition can be used for hemostatic management of patients suffering from hemorrhage associated with blood coagulation disorders, for example, disorders (including deficiency) of blood coagulation factors, especially caused by inhibitors (antibodies) against blood coagulation factors.
摘要翻译： 本发明提供了用于治疗和预防与血液凝固病症相关的出血的药物组合物，其包括活化的因子VII（FVIIa的）和因子X（FX）作为活性成分。 本发明的药物组合物不包含成分致病副作用，是安全的，高度有效的，且易于管理的止血。 该药物组合物可用于从与血液凝固病症相关的出血的患者的止血管理，例如，血液凝固因子的病症（包括缺乏症），爱尤其是抑制剂（抗体）针对凝血因子引起的。
-
4.发明授权FACTOR VIII OR VON WILLEBRAND FACTOR FOR THE TREATMENT OF HEMORRHAGIC DISEASES ASSOCIATING THROMBOPATHY 有权因子VIII或将触发因素thrombopathies出血性疾病关联的治疗
公开(公告)号：EP1240900B1
公开(公告)日：2009-05-06
申请号：EP00985824.2
申请日：2000-12-21
发明人： ARAKI, Tatsuya , TOMOKIYO, Kazuhiko , NAKATOMI, Yasushi , TESHIMA, Kaori , WATANABE, Tomoko , NAKAGAKI, Tomohiro
CPC分类号： A61K38/37 , Y10S514/802 , Y10S514/834
摘要： Medicinal compositions, which contain blood coagulation factor VIII and/or von Willebrand factor in an amount effective in hemostatis, for preventing and treating hemorrhagic diseases associating thrombopathy induced not by blood coagulation factor failures or von Willebrand factor failures but by a decrease in circulatory platelet count or abnormality in platelet function; and a method of treating hemorrhagic diseases which comprises administering blood coagulation factor VIII and/or von Willebrand factor in an amount effective in hemostatis to patients with the hemorrhagic diseases associating thrombopathy.
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
